|Articles|February 1, 2003

Varicella breaks out in a day-care center where the vaccination rate is high

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

FDA approves zilganersen (Zanvastro) as first treatment for Alexander disease

FDA approves zilganersen (Zanvastro) as first treatment for Alexander disease

ByMorgan Ebert, Executive Editor

September 3rd 2026

Evidence review supports respiratory virus immunizations for 2026-2027 season

Evidence review supports respiratory virus immunizations for 2026-2027 season

ByKevin Ault, MD, FACOG

September 3rd 2026

HPV vaccination coverage stalls for fourth straight year as rural-urban gap persists, CDC finds | Image Credit: © Halfpoint - stock.adobe.com

HPV vaccination coverage stalls for fourth straight year as rural-urban gap persists, CDC finds

ByMorgan Ebert, Executive Editor

September 3rd 2026

AAP recommends 2026-2027 COVID-19 vaccine for all infants 6 to 23 months and at-risk older children | Image Credit: © Jacob Lund - stock.adobe.com

AAP recommends 2026-2027 COVID-19 vaccine for all infants 6 to 23 months and at-risk older children

ByMorgan Ebert, Executive Editor

September 2nd 2026

A 17-year-old male with loss of consciousness during a febrile illness

A 17-year-old male with loss of consciousness during a febrile illness

BySimone Hunter, MBBS,Orhan Kilinc, MD

September 2nd 2026

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

Trending on Contemporary Pediatrics

AAP expands RSV immunization recommendations for high-risk children

Top 5 pediatric health headlines you missed in August 2026

AAP recommends 2026-2027 COVID-19 vaccine for all infants 6 to 23 months and at-risk older children

PCOS to PMOS: A long-awaited change

From primary care to specialist: Managing PMOS and insulin resistance